Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target

Cantor Fitzgerald analyst Carter Gould has reiterated an Overweight rating on Vaxcyte (NASDAQ: PCVX) and set a price target of $120 for the company's stock. This endorsement reflects confidence in Vaxcyte's potential performance in the market.